Park Medi World Q1 FY27 Results (NSE: PARKHOSPS)
Signal: Steady quarter
The read
The operating trajectory remains expansion-led: Q1FY27 revenue was ₹475.71 crore, EBITDA margin was 28.1% and PAT was ₹82.51 crore, while the announced ~1,500-bed rollout represents a 46% capacity addition; the main thesis variable is whether newly acquired and commissioned hospitals achieve the stated utilisation and earnings-accretion targets without weakening margins or capital discipline.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹475.71 Cr | N/A | +3.4% |
| EBIT | ₹114.89 Cr | N/A | |
| Net profit | ₹82.51 Cr | N/A | |
| EPS | ₹2.05 | N/A | |
| EBIT margin | 28.1% |
P&L walk
Consolidated revenue was ₹475.71 crore and EBITDA was ₹133.73 crore, producing a 28.1% EBITDA margin; PAT was ₹82.51 crore and remained supported primarily by operating earnings, with other income of ₹7.65 crore below 20% of PBT.
Segments
No segment table is disclosed; the ₹82.51 crore consolidated PAT versus ₹1.08 crore standalone PAT shows that subsidiaries and operating hospital entities are driving the group result.
Key positives
- Consolidated EBITDA was ₹133.73 crore and EBITDA margin was 28.1%, above the 24% OPM reported in Q3FY26 and consistent with the 28% OPM in Q4FY26.
- The group is pursuing a ~1,500-bed addition over twelve months, equivalent to a disclosed 46% capacity increase over the December 2025 closing bed count of ~3,250 beds.
- The ₹107 crore acquisition of Mehar Hospital-Zirakpur adds a 150+ bed multi-speciality facility in the Tricity catchment and is described by management as earnings-accretive.
- The target's turnover increased from ₹17.52 crore in FY24 to ₹19.10 crore in FY26, indicating an established operating base before Park-brand integration.
Key concerns
- The expansion programme adds ~1,500 beds across acquisitions, greenfield hospitals and extensions within twelve months, creating execution, ramp-up and utilisation risk that is not yet visible in the current quarter's operating KPIs.
- The Zirakpur acquisition requires approximately ₹107 crore of cash consideration for a target with FY26 turnover of ₹19.10 crore; the filing does not disclose target EBITDA, purchase accounting or expected payback.
- No occupancy, ARPOB, case mix, bed utilisation or hospital-level profitability data is disclosed, limiting assessment of whether the 28.1% consolidated EBITDA margin is sustainable as new capacity opens.
Research and educational content only. Not investment advice.